Search | Clinical Trials Finder

Conditions: Multiple Sclerosis
Interventions: Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more

Conditions: Multiple Sclerosis
Interventions: Interferon-beta-1a FBS-free/HSA-free; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more

Conditions: Multiple Sclerosis
Interventions: Mycophenolate Mofetil (CellCept); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas

Conditions: Multiple Sclerosis, Low Bone Density
Interventions: Copaxone, Interferon-beta 1a, Interferon-beta 1b; Drug
Lead sponsor: Nancy Hammond, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Multiple Sclerosis
Interventions: Avonex (Interferon beta 1a), Riluzole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Rebif New Formulation Non Titrated, Rebif New Formulation Titrated; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions: interferon beta 1a, methotrexate, methylprednisolone; Drug
Lead sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Buffalo, New York • Cleveland, Ohio + 1 more

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Interferon Beta-1A, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Computed Tomography, Positron Emission Tomography, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BIIB017 (peginterferon beta-1a), Interferon beta type 1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: Multiple Sclerosis
Interventions: Rebif®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: Up to 18 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B; Other
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Rebif, Tecfidera; Drug
Lead sponsor: IMS HEALTH GmbH & Co. OHG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more

Conditions: Active Ulcerative Colitis
Interventions: BG9418 (Interferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Lakewood, Colorado • Bristol, Connecticut + 2 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for Teriflunomide), Interferon-β; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Plegridy, Prednisone, Tylenol Pill; Drug
Lead sponsor: Holy Name Medical Center, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Teaneck, New Jersey

Search by objective public record fields.

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Treatment Interruption of Natalizumab

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

Rebif New Formulation (RNF) Quality of Life (QOL) Study

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Avonex 15 Year Long Term Follow-up Study

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

Adherence Trial With MS LifeLines ® Services

Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects